US company secures genetically modified rice ban against Chinese rival

Kansas-based company wins block on infringing plant-based albumins | Genetically programmed rice expresses human proteins used in immunotherapy drugs, gene therapies and vaccines.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

UPDATED: ITC blocks Chinese imports of rice-derived rHSA products after ALJ review

20 October 2022 Commission overturns one ALJ finding but affirms all others, agreeing that Wuhan Healthgen infringed Ventria's rice seed patent | Dispute concerns recombinant human proteins derived from genetically engineered rice.

Americas

USITC to probe alleged engineered-rice theft by Chinese company

19 January 2021 The US International Trade Commission is to investigate allegations that a Chinese company infringed patents held by Ventria Bioscience by importing genetically-engineered rice seeds for medical purposes.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

US company secures genetically modified rice ban against Chinese rival

More on this story

Editor's picks

Editor's picks

More features